• LUTS relief based on reduction in IPSS (questionnaire) [ Time Frame: After 4, 8 and 12 weeks treatment compared to Baseline ] [ Designated as safety issue: No ]
• Evaluate changes in the concentration of testosterone in the serum [ Time Frame: After 4, 8 and 12 weeks treatment compared to Baseline ] [ Designated as safety issue: No ]
• Evaluate changes in the concentration of Prostate Specific Antigen (PSA) in the serum [ Time Frame: After 4, 8 and 12 weeks treatment compared to baseline ] [ Designated as safety issue: No ]
• Evaluate changes in the concentration of oestradiol in the serum (blood) [ Time Frame: After 4, 8 and 12 weeks treatment compared to baseline ] [ Designated as safety issue: No ]
• Evaluate patients' Quality of life based on questionnaire [ Time Frame: After 4, 8 and 12 weeks treatment compared to baseline ] [ Designated as safety issue: No ]
• Safety (Adverse events and laboratory values) [ Time Frame: As applicable ] [ Designated as safety issue: Yes ]

The purpose of this trial is to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who are scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, hormone therapy will be given for three months and patients will be randomly selected (like flipping a coin) to receive either Degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide) The prostate size will be measured by ultra sound at the beginning and at the end of the trial and patients will be required to come to the clinic for 5 or 6 visits during the three months.

• Drug: Degarelix
• Drug: Goserelin (Zoladex®) combined with anti-androgen flare protection bicalutamide (Casodex®)

Inclusion Criteria:

• Patient has given written informed consent before any trial-related activity is performed.
• Has a confirmed prostate cancer in which this type of treatment is needed.

Exclusion Criteria:

• Previous treatment for prostate cancer
• Previous trans-urethral resection of the prostate
• Patients who are lymph node positive or have other metastatic disease
• Use of urethral catheter
• Current treatment with a 5-alpha reductase inhibitor or α-adrenoceptor antagonist.
• History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema.
• Hypersensitivity towards any component of the investigational product
• Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer.
• Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk)
• Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.